diarrhea on a glp 1 GI Adverse Effects of Glucagon-Like Peptide-1 Receptor Agonists Managing GLP-1/GIP side effects with

Description

Setting realistic expectations, attending regular follow-up appointments and making long-term lifestyle changes can help maximise the benefits of treatment while supporting lasting weight management

Semaglutide, Tirzepatide, and Retatrutide suppress food intake in triple humanized Incretin-receptor mice

This is associated with reduced noradrenaline content in the pancreas and blocked by an 2 -adrenergic receptor agonist, implicating functional involvement of the sympathetic nervous system (SNS)

Reduction of Glucagon : These medications decrease the secretion of glucagon, a hormone that raises blood sugar levels, further aiding in maintaining optimal glucose levels

Los autores del trabajo consideran que este tratamiento debera considerarse en pacientes con diabetes obesos o con sobrepeso, aunque es necesario continuar los estudios para conocer exactamente los efectos de los agonistas de los receptores de GLP-1 en el abordaje de la obesidad en pacientes sin diabetes